BOTHELL, WA - July 7, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound, today announced the introduction of its new 6 pound NanoMaxx™ ultrasound tool, the latest addition to SonoSite’s suite of specialized products for point-of-care visualization in medicine. Designed for diagnostic imaging, clinical assessment and procedural guidance at the hospital bedside and in the physician’s office, the NanoMaxx system is the company’s latest innovation in point-of-care user design and features one button system control. SonoSite has begun deliveries to international customers and is waiting FDA 510(k) clearance to begin US customer shipments.

“The NanoMaxx tool makes high quality ultrasound available to a much broader range of clinicians and applications, all of which can save time and money and improve patient safety,” said Kevin M. Goodwin, SonoSite President and CEO. “The healthcare world is changing dramatically and the NanoMaxx is part of our continuing effort to make ultrasound a more affordable and useful tool in the world of medicine.”

“The NanoMaxx system offers our gold standard durability and two-hour battery life along with image quality similar to our flagship M-Turbo® system. A fluid-resistant user interface makes the system easy to clean and disinfect, helping to address the growing concern over infection control. Designed and manufactured at SonoSite’s headquarters in Bothell, Washington, USA, the NanoMaxx system and its transducers again offer our industry-leading 5-year warranty to deliver the lowest cost of ownership in ultrasound,” Mr. Goodwin said.

One Button Technology Optimizes Workflow
Based on SonoSite’s 4th generation Turbo technology platform, the NanoMaxx system incorporates proprietary, advanced imaging algorithm technologies, including ColorHD™ to deliver exceptional image quality in a lightweight, rugged form factor.

With a touch screen that responds easily to the tap of a finger, and one button optimization, clinicians can readily acquire high resolution images to increase clinical productivity at the point-of-care. A system boot-up time of less than 20 seconds and long battery life further enhance workflow when using the NanoMaxx system.

Designed to Help Hospitals Meet New Standards of Care
Clinical studies have proven that bedside ultrasound increases the accuracy of interventional procedures and it is now recommended by two government-based agencies¹ and three US medical societies.² At introduction, the NanoMaxx tool is available with a complement of five transducers to support a wide range of examinations and procedures including thoracic assessment for hemothorax, hydrothorax and pneumothorax, vascular access, needle aspirations and injections, as well as abdominal, cardiac, nerve, OB/Gyn, musculoskeletal, small parts and vascular scanning.

The clinical capabilities of the NanoMaxx will help eliminate the risk and cost of transporting patients to the imaging lab for many examinations and procedures.

Mount it. Carry it. Or Use it on a Stand
The small footprint of the NanoMaxx system, along with its space-saving solutions, enables seamless integration with a variety of exam-room configurations. It can be wall mounted, placed on an exam table, or used from a highly maneuverable stand. Physicians can easily carry the NanoMaxx tool from room-to-room, to a satellite office, the operating room or to a field site for immediate use.

Built to Last
The NanoMaxx system’s highly integrated architecture and ruggedized design, including the industry’s first elastomeric bumper for extra durability, allows it to be used in the most austere and demanding environments. A magnesium shell that is significantly stronger and lighter than plastic helps to protect the system against accidental droppage. As with all SonoSite systems, the NanoMaxx ultrasound tool and its transducers are built to withstand a one meter drop test.

Web-Based Demonstration and Purchasing Program
SonoSite’s One-to-One Purchase Program further extends the cost saving advantages of the NanoMaxx ultrasound tool by replacing or complementing the traditional on-site, pre-sale demonstration with a personal phone consultation and webcast demonstration provided by a professional clinical sales consultant. Visit the NanoMaxx ultrasound tool website to learn more about SonoSite’s newest system and to experience a personal, interactive product demo. In addition, Apple® iPhone™ and iPod™ mobile device users can view a video of the NanoMaxx system on SonoSite’s new SonoAccess™ application.

______________________________________

¹ Agency for Health Care Research and Quality (AHRQ) report: Making Healthcare Safer: A Critical Analysis of Patient Safety Practices 2001.

The American College of Emergency Physicians.“Policy Statement; Emergency Ultrasound Guidelines.” 53 (2009): 550-70.

______________________________________

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 700 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy and effectively integrate acquired products and operations, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

iPhone is a trademark of Apple, Inc.

BOTHELL, WA, June 24, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for point-of-care medicine, announced today the launch of the SonoAccess™ application, the first medical iPhone app from an ultrasound company that provides a multimedia library of ultrasound resource materials for medical professionals to access when and where they need it.

The SonoAccess application is an iPhone or iPod touch® interactive mobile learning application that addresses the continuing educational needs of point-of-care ultrasound users. SonoSite partnered with leading physicians to gather and create clinical education materials for emergency medicine, critical care and anesthesia with other specialties to be added soon. Users can access high quality instructional videos, case studies and reimbursement guides, as well as reference nearly 100 clinical images and news feeds on SonoSite. In addition, users can customize their user profiles to generate recommended lists of videos specific to their practice, as well as share videos, case studies and images with their colleagues and friends. The SonoAccess application is available for free download at www.sonosite.com/products/sonoaccess.

“Physicians need practical tutorials on ultrasound procedures,” said Dr. David Auyong, Anesthesiologist, Seattle, WA. “There are not a lot of resources that give simple, practical tips on how to optimize the position of the probe or position the patient. Having a resource for continuing education available 24/7 like this will be helpful.”

Dr. Phillips Perera, MD, FACEP, RDMS, Emergency Ultrasound Program Director at Columbia University Medical Center, New York Presbyterian Hospital, NY, estimates that at his hospital a large proportion of the faculty and residents have either an iPhone or iPod touch and thinks many will find the SonoAccess application to be helpful. Dr. Perera has already found the application to be a useful tool when teaching residents.

“We have learned that using video works very well for teaching ultrasound—you don’t get the same impact from textbooks. I can use SonoAccess even while teaching a resident to perform an ultrasound exam at the bedside by propping up the iPhone next to the bed and pointing out on an image ‘this is the heart chamber you are looking for,’ for example,” Dr. Perera said.

“The portability of SonoAccess matched with the short, bullet point education modules make this a great fit for the busy lifestyle of emergency physicians and residents,” Dr Perera said.

With 28 instructional ultrasound videos, and 17 video case studies, the SonoAccess application is one of the largest free resources of instructional videos for point-of-care ultrasound and demonstrates SonoSite’s continued commitment to education. To view a demo video of SonoAccess visit www.sonosite.com/products/sonoaccess.

Slalom Consulting, a national management consulting and technology solutions firm with mobility expertise, worked with SonoSite on the design and development of SonoAccess to deliver the industry’s first interactive mobile learning application from an ultrasound company.

This is SonoSite’s second education initiative with Apple®. In 2006 SonoSite introduced video refresher courses for the iPod to give physicians an easy to access source of information to use in their practice.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 700 people worldwide.

iPhone and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.

BOTHELL, WA, June 11, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for point-of-care medicine, announced today that it has begun customer shipments of the SonoRemote™ Control, a compact voice or touch activated solution for adjusting ultrasound controls at a distance when using SonoSite M-Turbo® or S Series™ systems.

Approximately the size of an iPhone® and using Bluetooth® technology, the SonoRemote Control is capable of adjusting essential system parameters – Depth, Gain, Freeze and Save – within 10 meters of the ultrasound system. With voice activation or when used in a sterile sheath, the SonoSite remote control eliminates the need to break the sterile field during interventional procedures. And with a tactile reference keypad the user does not have to look at the remote to identify which button to press—even the touchpad has been designed with increased workflow in mind.

Dr. Ben DuBois, MD, orthopedic shoulder specialist in San Diego, explains how the remote can help in his practice: “With any ultrasound guided needle placement for joint injections I am using both hands and am unable to save or freeze the ultrasound image without having a medical assistant in the room to help. However, tying up my assistant just to push a button is not an efficient use of their time; it slows down patient flow, and limits the number of patients we can see in a day. With the remote I would be able to do the injection and run the ultrasound system myself without having to waste anyone’s time.”

The SonoRemote Control is programmable to any voice or language, has been drop tested from 3 feet and with its sealed keypad can be safely and easily cleaned with hospital grade disinfectant, important for infection control.

For more information visit: www.sonosite.com/products/sonoremote

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 700 people worldwide.

Expands SonoSite’s Sales Channel to Large Market for Cardiovascular Disease Management

BOTHELL, WA - June 9, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, today announced that it has reached an agreement to acquire CardioDynamics International Corporation (Nasdaq:CDIC). Under the terms of the agreement, SonoSite will acquire CardioDynamics in exchange for $1.35 per share in cash. The aggregate transaction value will be approximately $10.0 million, or $12.3 million net of cash and debt.

CardioDynamics reported revenues of $24.5 million in 2008. Its impedance cardiography (ICG) product line provides non-invasive assessment of cardiac output and other hemodynamic parameters in the physician’s office, outpatient clinic or hospital. This information allows physicians to assess and diagnose underlying cardiovascular disorders, customize and target treatment, monitor the effectiveness of prescribed medications and identify potential complications. The company’s latest generation product, the BioZ® Dx system, integrates ICG with electrocardiography (ECG), providing the ability to assess both mechanical and electrical cardiovascular function.

“The acquisition of CardioDynamics is part of a strategic initiative that moves SonoSite forward toward our long-stated goal of adding clinical value and reducing healthcare system costs in cardiovascular disease management. CardioDynamics is the platform we will build upon to achieve this goal,” said Kevin M. Goodwin, SonoSite President and CEO.

Mr. Goodwin continued, “CardioDynamics offers non-invasive, cost saving products and technology. Current products, as well as those in the pipeline, represent attractive innovation opportunities for point-of-care medicine. In addition, CardioDynamics has established a solid direct sales channel in the U.S. with 38 sales representatives calling on cardiologists, internal medicine and family medicine practitioners, primarily in physician office settings. We believe we can leverage this channel to build on our existing footprint in point-of-care markets.”

“This milestone event is an important acknowledgement of the value that CardioDynamics has produced in creating a new technology for the assessment of cardiovascular disease,” said Michael K. Perry, CEO of CardioDynamics. “We are pleased to join with an industry leader in point-of-care medicine who shares our vision of creating non-invasive technologies that improve outcomes and reduce the cost of patient care. The expanded platform that the combination with SonoSite provides will benefit our customers, employees and shareholders.”

The acquisition is conditioned upon approval by CardioDynamics’ shareholders as well as the satisfaction of other customary conditions. Approval by SonoSite’s shareholders is not required. The transaction is expected to close in the third quarter of 2009.

GCA Savvian acted as financial advisor and Fenwick & West LLP acted as legal counsel to SonoSite. Cain Brothers and Company LLC acted as financial advisor and Pillsbury Winthrop Shaw Pittman LLP acted as legal counsel to CardioDynamics.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 700 people worldwide.

About CardioDynamics
CardioDynamics is the innovator and a leader in the development, manufacture and distribution of noninvasive Impedance Cardiography (ICG) diagnostic and monitoring devices and proprietary ICG sensors. For additional information, please refer to the company’s Web site at www.cdic.com.

Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed merger. In connection with such proposed merger, CardioDynamics has agreed to file a proxy statement and other materials with the SEC. The proxy statement will be mailed to the stockholders of CardioDynamics. We urge investors to read the proxy statement and these other materials carefully when they become available because they will contain important information about CardioDynamics and the proposed merger. You will be able to obtain the proxy statement, as well as other filings containing information about CardioDynamics, free of charge, at the website maintained by the SEC at www.sec.gov. Copies of the proxy statement and other filings made by CardioDynamics with the SEC can also be obtained, free of charge, by directing a request to CardioDynamics, 6175 Nancy Ridge Drive, Suite 300, San Diego, California 92121, Attention: Chief Financial Officer.
Information regarding the identity of the persons who may, under SEC rules, be deemed to be participants in the solicitation of stockholders of CardioDynamics in connection with the transaction, and their interests in the solicitation, will be set forth in a proxy statement that will be filed by CardioDynamics with the SEC.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

BOTHELL, WA - May 15, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, today announced that Medical Simulation Corporation (MSC) has selected SonoSite’s M-Turbo® ultrasound as their preferred system for teaching clinicians central line placement procedures for their SimSuite® Central Line Management Program. MSC is the leader in providing full-service simulation training and education services to healthcare personnel, medical societies and medical product manufacturers.

“Medical Simulation Corporation is proud to partner with SonoSite as its preferred ultrasound vendor for the SimSuite Central Line Management Program,” Bill Younkes, MSC President and CEO said. “Throughout the selection process, SonoSite’s M-Turbo ultrasound system rose to the top in head-to-head demonstrations with multiple vendors and met our needs for portability and exceptional image quality. Along with their 5-year warranty; SonoSite’s work with the military speaks volumes about their system’s reliability.”

SonoSite’s M-Turbo technology enables clinicians to confidently perform central line placement procedures. The system’s proprietary imaging technologies — SonoMB™, SonoHD™ and SonoAdapt™, provide healthcare professionals with crystal-clear imaging, better edge detection and needle recognition, for ultimate visual guidance.

For a product demonstration, interested clinicians can visit both SonoSite (Booth #3418) and Medical Simulation Corporation (Booth #1951) at the American Association of Critical-Care Nurses’ (AACN) National Teaching Institute (NTI) and Critical Care Exposition, the world’s largest conference for nurses who care for acutely and critically ill patients. The conference is being held May 19-21st, in New Orleans at Ernest N. Morial Convention Center. Click here to watch a video about MSC’s SimSuite program and to learn more about the use of SonoSite’s M-Turbo ultrasound in the Central Line Management Program.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 650 people worldwide.

About Medical Simulation Corporation
Medical Simulation Corporation (MSC) is the recognized healthcare industry leader in providing full-service simulation training and education services to healthcare personnel, medical societies and medical product manufacturers. MSC’s patient safety solutions are designed to strengthen the competence and confidence® of nurses, physicians and technologists. Through its network of training platforms, MSC can provide customized training services to any location worldwide. For more information, please visit www.medsimulation.com or call 888/889-5882.

BOTHELL, WA - April 27, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, today announced financial results for the first quarter ended March 31, 2009.

First quarter 2009 worldwide revenue was $51.8 million, a decrease of 1% over the prior year’s first quarter as previously announced. Changes in foreign currency rates decreased worldwide revenue in the first quarter of 2009 by approximately 8%.

Total US revenue grew 5% in the quarter to $23.2 million driven by more than doubling of revenue in the enterprise channel. US direct hospital sales were negatively impacted by the slowdown in hospital capital spending - down 14%. International sales were down 6% to $28.6 million due to a 14% negative foreign exchange impact. On a constant currency basis, international sales were up 8%.

The company reported operating income (EBIT) of $1.6 million compared to $2.4 million, a decline of 34% compared to Q1 2008. Operating income excluding stock-based compensation expense (EBITS) was $4.1 million compared to $4.3 million in the prior year.

“We made expense reduction and efficiency progress in the quarter in the face of expected revenue softness,” said Kevin M. Goodwin, SonoSite President and CEO. “We also improved our balance sheet in the quarter by repurchasing $25 million of our long-term convertible notes at a discount. Additionally, we reduced the quarter’s operating expenses by $1.9 million and have revised our expense improvement goal for up to a 10% reduction over the prior year. We expect the economic environment and visibility to remain challenging for several quarters, thus our priority is to remain focused on continuous streamlining or “leaning” of our business model while setting up a return to growth with key strategic investments.”

The company reported net income of $863,000 for the first quarter of 2009, or $0.05 per diluted share, compared to $190,000 or $0.01 per diluted share in 2008. These results were significantly affected by the adoption of APB 14-1, as of January 1, 2009 relating to the accounting treatment for convertible debt.

Total operating expenses in the first quarter declined 5% to $33.5 million compared to the first quarter of 2009. The company reduced SG&A expense by 12% to $25.8 million compared to the prior year quarter. R&D investment grew 24% in the first quarter to $7.7 million, as planned.

Other expense in the quarter included $2.6 million of interest expense, of which $1.2 million was from the adoption of APB 14-1, that offsets a $1.3 million gain from the repurchase of $25.0 million of senior convertible notes.

As of March 31, 2009, the company held $258 million in cash and investments and outstanding senior convertible notes of $120 million.

Company Updates Outlook for 2009
“Our view remains that the worldwide economy will continue to be challenging with difficult visibility. We see signs of opportunity and growth offset by a strong headwind from US Hospital market softness and the stronger dollar,” Mr. Goodwin said. “We assume that the US dollar will continue to strengthen and that changes in foreign currency will have a negative effect of 4 -5% on revenue. We therefore expect that the company’s 2009 revenue could potentially be flat to down 10% as compared to 2008. We are responding by increasing our expense reduction targets to a range of 5-10%, from the previous goal of 5%.”

“We intend to continue introducing innovative and cost effective new products as the year proceeds,” Mr. Goodwin said.

The company expects non-cash interest expense of $4.9 million for the year from the adoption of APB 14-1 and an annual tax rate of approximately 39%.

Note on Adoption of FSP No. APB 14-1
The company adopted FSP APB 14-1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement),” (”APB 14-1″) on January 1, 2009, which required the company to account separately for the liability and equity components of its convertible debt in a manner that reflects a nonconvertible debt borrowing rate. APB 14-1 requires retrospective application of this standard. Accordingly, the company’s operating results since the issuance of the senior convertible debt and future operating results will reflect additional non-cash interest expense.

The following table presents the three months ended March 31, 2009 and 2008 with and without the impact of APB 14-1 for comparison purposes (unaudited):

The following table presents our 2008 quarterly results as adjusted for the impact of APB 14-1 (unaudited):

Conference Call Information
SonoSite will hold a conference call on April 27th at 1:30 pm PT/4:30 pm ET. The call will be broadcast live and can be accessed via the “Investors” Section of SonoSite’s website at www.sonosite.com. A replay of the audio webcast will be available beginning April 27, 2009, 5:30 pm PT and will be available until May 11, 2009, 9:59 pm PT by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 8899954 is required to access the replay. The call will also be archived on SonoSite’s website.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 650 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

A replay of the audio webcast will be available beginning April 27, 2009, 5:30 pm PT and will be available until May 11, 2009, 9:59 pm PT by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 8899954 is required to access the replay. The call will also be archived on SonoSite’s website.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 650 people worldwide.

BOTHELL, WA - April 6, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, today provided preliminary revenue results for the first quarter ended March 31, 2009.

The company said worldwide revenue decreased by 1% - 2% in Q1 2009 compared to Q1 2008. On a constant currency basis, worldwide revenues grew 6% - 7% in the quarter, indicating a currency headwind of approximately 8%.

US revenues grew approximately 4% year over year. Continued slowing of US hospital capital spending drove a mid-teen percentage decline in SonoSite’s US hospital revenues. This was offset by excellent growth in the company’s US enterprise channel. International revenues decreased approximately 6% in the quarter, driven by the impact of a weaker dollar. On a constant currency basis the International sector was up approximately 8% in Q1 2009 on a year over year basis.

These revenue estimates are preliminary. The company will report full financial results for the first quarter on April 27, 2009 after the close of market.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs approximately 650 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

BOTHELL, WA - April 2, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for the point-of-care, will demonstrate its latest advances in connectivity and workflow integration technology on the SonoSite Turbo™ platform, during the Healthcare Information and Management System Society (HIMSS) 2009 Conference. The conference is being held in Chicago at McCormick Place, April 4-8th.

As a participant at the HIMSS’ Interoperability Showcase, SonoSite will conduct live demonstrations on its M-Turbo® system to show how it communicates with multiple DICOM® compliant products to expedite workflow. Both the M-Turbo and S Series™ product lines support the following DICOM functions: Storage Commitment, Modality Performed Procedure Step (MPPS), Modality Work List (MWL), Print and Archive.

SonoSite’s participation in the HIMSS exhibit is based on its success at the 2009 North America Connectathon, in February, when SonoSite passed a series of tests that successfully demonstrated its versatile communication capabilities.

“SonoSite’s expanded connectivity options provide a flexible and robust solution for seamlessly connecting ultrasound to the medical information environment,” said David Prager, Manager, Hospital Infrastructure Technology (HIT) at SonoSite. “Our goal is to simplify physician’s workflow by automating scheduling and archiving activities for images and data collected during the exam.”

Learn more about SonoSite’s connectivity options by visiting www.sonosite.com/connect.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

About HIMSS
The Healthcare Information and Management Systems Society (HIMSS) is the healthcare industry’s membership organization exclusively focused on providing global leadership for the optimal use of healthcare information technology (IT) and management systems for the betterment of healthcare. Founded in 1961 with offices in Chicago, Washington D.C., Brussels, and other locations across the United States and Europe, HIMSS represents more than 20,000 individual members and over 300 corporate members that collectively represent organizations employing millions of people. HIMSS frames and leads healthcare public policy and industry practices through its advocacy, educational and professional development initiatives designed to promote information and management systems’ contributions to ensuring quality patient care.

*DICOM is a registered trademark of NEMA

The new L52x/10-5 MHz transducer is the eighth transducer to join SonoSite’s suite of veterinary probes and is compatible with both SonoSite’s M-Turbo® and S-VetMed™ ultrasound products. For ultimate exam convenience and efficiency, the SonoRemote control is based on Bluetooth® wireless technology, can be voice or touch activated and can adjust system controls from within a radius of 10 meters.

“A wireless remote control is a ground-breaking innovation for veterinarian ultrasonography. The freedom that SonoSite’s remote control will provide during an equine ultrasound exam will significantly improve clinical efficiency and safety,” said Diane Isbell, DVM, Livermore, California. “With the SonoRemote control, I will be able to maintain a safe working distance between my patient, the ultrasound system and me while efficiently working through my examination.”

Based on veterinarian input, the robust, ergonomically designed L52x intracavitary transducer provides high-resolution imaging and superior image quality, enabling the examination of fine ovarian and uterine structures, as well as the lower lumbar and medial to lateral view of the animal’s hip. Built for durability, the technologically advanced transducer features a unique cable jacket built from material engineered to withstand even the harshest of environments. To enhance productivity, the L52x was designed to fit comfortably and naturally in the hand of a veterinarian. With a textured surface, veterinarians can easily grip the probe and keep a firm grasp, without the need for added pressure.

SonoSite offers a 2-year warranty on the new veterinary L52x transducer coupled with its industry-leading 5-year warranty on the ultrasound systems and all other veterinary transducers. Vet Imaging and Aloka, Inc., SonoSite’s partners for the veterinary medicine market in North America, are distributors of the new transducer and remote control.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 640 people worldwide.

BOTHELL, WA - February 12, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, today announced financial results for the fourth quarter and full year ended December 31, 2008.

Fourth quarter 2008 worldwide revenue grew to $70.2 million, an increase of 8% over the fourth quarter of 2007. Full year 2008 revenue grew to $243.5 million, up 19% over 2007. Changes in foreign currency rates decreased worldwide revenue in the fourth quarter by 4.2% and had a favorable impact of 0.6% on the year.

The company reported a net income increase of 184% for the fourth quarter of 2008 to $12.1 million or $0.69 per diluted share, compared to $4.3 million or $0.25 per diluted share in 2007. For the full year net income grew 199% to $20.6 million, or $1.18 per diluted share, compared to $6.9 million, or $0.40 per diluted share in 2007.

Net income in the fourth quarter and full year 2008 included a non-recurring, pre-tax charge of $3.0 million from terminated acquisition talks and severance payments, as well as a $15.7 million pre-tax gain from the repurchase of $80.3 million of senior convertible notes.

During the fourth quarter of 2008, US revenue grew 3% to $33.7 million and was impacted by a slowdown in capital spending at US hospitals. International business grew 14% to $36.5 million in the fourth quarter and continued to deliver broad-based double digit growth, but was negatively impacted by 8.5% from foreign exchange rate changes. For the full year, US revenue grew approximately 12% to $116.7 million and international revenue grew 26% to $126.8 million.

Total operating expenses in the fourth quarter increased 8% to $42.7 million, and increased 7% for the full year to $147.4 million. Including the previously mentioned $3.0 million non- recurring charge, SG&A expenses grew 4% in the fourth quarter and 6% for the full year. R&D expenses increased 30% in the fourth quarter and 11% for the full year. Stock-based compensation increased by $1.9 million in the fourth quarter, primarily as the result of a change in the future forfeiture rate assumptions.

As of December 31, 2008, the company held $279.7 million in cash and investments and long-term debt of $144.7 million, for net liquidity of $135.0 million.

“2008 marked a year of excellent progress for the company. We exceeded our original full year guided targets of 15% revenue growth with 7-8% operating margins,” said Kevin M. Goodwin, SonoSite President and CEO. “The drivers of our performance included the new M-Turbo® and S Series™ product lines alongside excellent execution throughout the company. We delivered a 5-fold increase in operating income with more than a quadrupling of operating margins. We began to demonstrate operating leverage from our business model that we have always believed possible. Further, our net liquidity improved by $50 million during the year.”

“Our international business delivered another strong quarter and year with double digit gains across all major geographic regions,” Mr. Goodwin said. “Our US business performed well throughout the year, although it was significantly hampered by customers deferring orders which had an estimated negative impact of 10% on worldwide revenue for the quarter. During the year, we delivered several new products and upgrades to our S Series and M-Turbo product lines which extended their footprint into new clinical markets. In 2009, we plan to continue entering new clinical markets while delivering more new products that will continue our tradition of innovation that helps make healthcare faster and less expensive while improving patient safety.”

Company Updates Outlook for 2009
“We expect that the worldwide economy will continue to be challenging and difficult to predict and now do not expect there to be any meaningful recovery until 2010,” Mr. Goodwin said. “Our primary financial objective in 2009 is to maintain and build upon our long-term earnings power and growth capacity. Our goal is to increase operating income at least 10% in 2009. To position ourselves for improved profitability in this difficult economic environment we are targeting a 5% reduction in our operating expenses from 2008 levels to approximately $140 million. Assuming current exchange rates, foreign currency will have a negative impact of 3-4% on revenue growth. Given the continued deterioration of the global economic markets and the slowdown in US hospital capital spending, we are not providing revenue or other financial guidance at this time.”

“While the current economic environment is uncertain, we are in the strongest position in our history as a company in terms of market share, innovation and growth opportunities,” Mr. Goodwin said. “Our products are becoming essential tools for patient safety and clinical productivity. We expect to continue building our financial strength, growth and earnings power going forward.”

Conference Call Information
SonoSite will hold a conference call on February 12th at 1:30 pm PT/4:30 pm ET. The call will be broadcast live and can be accessed via the “Investors” Section of SonoSite’s website at www.sonosite.com. A replay of the audio webcast will be available beginning February 12, 2009, at 4:30 pm (PT) until February 26, 2009, at 10:00 pm (PT) by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 7024347 is required to access the replay.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Download Selected Financial Information (PDF)

BOTHELL, WA- January 30, 2009- SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for point-of-care medicine, announced today that its new SonoGT™ Global Target technology is now available on SonoSite’s award-winning, mountable S Series™ ultrasound tools. The new performance platform delivers enhanced color flow sensitivity, wireless connectivity, including a remote control for hands-free system control and workflow integration for multiple point-of-care application markets.

First introduced for SonoSite’s versatile M-Turbo® systems in October 2008, SonoSite now brings the powerful SonoGT engine to effectively transform the S Series product line into the S-Turbo Series™. SonoSite plans to begin customer shipments of the new S Series systems with SonoGT technology in February. Customers can separately purchase SonoGT technology and upgrade existing S Series systems via an easy software download from a USB thumb drive. The SonoGT technology platform adds the following capabilities to the S Series product line:

Color Flow Performance
ColorHD™ Technology – A proprietary, color Doppler algorithm that harnesses the power of the S Series system’s digital signal processor to increase color, sensitivity and frame rates. Available on all transducers, ColorHD technology works in parallel with multiple Turbo platform algorithms, including SonoHD™ imaging technology, to provide increased diagnostic information and better visualization of color flow, particularly in low flow states.

Wireless Solutions
SonoRemote™ Control – A new tool enabled by the SonoGT technology platform untethers the clinician from the ultrasound system during procedures to increase ergonomic comfort to perform more easily in sterile field procedures. Based on Bluetooth® wireless technology, the SonoRemote control can be voice or touch activated and function from within a sterile bag or sheath. Clinicians can adjust system controls remotely from within a radius of 10 meters. SonoSite plans to begin shipping this option in the first quarter of 2009.

SonoRoam™ Technology – Using 802.11b/g technology, SonoRoam technology enables wireless image transfer from the S Series system to a PACS system via DICOM® and to a personal computer via SonoSite’s SiteLink™ so that clinicians can quickly retrieve the information from any location. Wireless connectivity is increasingly viewed as a critical component to reduce medical errors and speed time to diagnosis in a point-of-care ultrasound system.

Workflow Integration
DICOM Storage Commit and DICOM Multi-Modality Performed Procedure Step have been added to the S Series system to complete the IHE profile (Integrating the Healthcare Enterprise) Scheduled Workflow (SWF) Integration Profile. This facilitates seamless clinical integration of ordering, scheduling, image acquisition, storage, viewing and billing of patient procedures.

Patient Management – Patient demographics can now be entered before, during or after the exam. This allows flexibility in getting the procedure completed in time-critical situations where documentation is secondary to that of the procedure itself. In addition, there are new capabilities to facilitate more efficient processing of emergency medicine worksheets and reports. DICOM Multi-Modality Worklist (MWL) queries can be made to the hospital information network to gain quick access to patient scheduling for ultrasound and non-ultrasound procedures. SonoGT technology also enables physicians to annotate images and on-screen body markers for enhanced documentation of studies and procedures on S Series products.

New USB Bar Code Reader – This accessory allows clinicians to quickly and accurately enter patient information and update exam information prior to its entry into the patient record. SonoSite’s bar code reader is powered through a USB port thereby freeing AC power for another device.

New Transducer Options
C11x/8-5 MHz – a new addition to both the S-Nerve™ and S-ICU™ systems for neonatal and abdominal exams and includes vascular settings.

L25x/13-6 MHz – offers an ophthalmic exam setting for the S-FAST™ tool for the evaluation of globe rupture, intraocular foreign bodies, and retinal detachment.

SLAx/13-6MHz – is now configured with the S-MSK™ and S-Nerve systems for nerve and vascular scanning applications.

View a Demonstration of the New SonoGT Platform
SonoSite is demonstrating SonoGT technology at the 38th Congress of the Society of Critical Care Medicine, Booth #635, being held in Nashville, Tennessee from February 1-3.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

Bluetooth and DICOM are registered trademarks or trademarks of their respective owners.

“The S-Women’s Health is great to have in the exam room because if a patient comes in with a lump, I am able to quickly and easily determine if it is something like fibrocystic thickening, or if it requires additional evaluations,” said Deanna J. Attai, MD, FACS, Center for Breast Care in Burbank, California. “When you consider the quality and affordability of the system and the fact that you can pick it up and take it to the operating room, you just can’t get a better tool for your practice than the S-Women’s Health system.”

The S-Women’s Health ultrasound tool is designed with women’s health clinicians in mind. It is sophisticated, yet simple and easy to use. Buttons, dials and menus have been eliminated from the interface, with the exception of two controls- Depth and Gain- for acquiring the optimum image quality. SonoSite’s proprietary advanced technologies, SonoHD™ and SonoMB™, are incorporated, providing crystal-clear imaging and enabling the physician to visualize minute details. With the capacity to zero-in on a targeted area, SonoSite’s advanced SonoAdapt™ technology enables the clinician to confidently locate masses, target lesions, guide biopsies, and initiate a course of treatment.

The S-Women’s Health tool has an award-winning design and is engineered to be placed on a stand or mounted on an exam room ceiling or wall to be easily accessible at the examining table. The system is configured to work with four broadband transducers to provide high resolution superficial, abdominal, vascular and pelvic imaging, allowing physicians to address a wide spectrum of women’s health concerns. This full functionality is complemented by SonoSite’s unsurpassed, industry-leading 5-year warranty, which covers the system and transducers and eliminates the need for costly annual service contracts.

Dr. Attai commented, “Not only does SonoSite have superior products, but they also have superior service. The 5-year warranty on their products means that not only will they repair the system if needed, they will get a loaner to me the very next morning. I can’t practice without my ultrasound system and SonoSite recognizes that.”

SonoSite offers extensive training and education programs delivered on site, online, and in collaboration with leading medical institutions and educators.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

BOTHELL, WA - January 12, 2009 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for the point-of-care, today provided preliminary revenue results for the fourth quarter and year ended December 31, 2008. The company said that fourth quarter revenue grew 8% to approximately $70 million compared to the prior year’s fourth quarter. For the year, worldwide revenue is estimated to have increased by 19% to approximately $243 million. Changes in foreign currency rates decreased worldwide revenue by an estimated 4% in the fourth quarter and had a favorable impact of 0.6% on the year.

“The M-Turbo® and S Series™ product lines drove a year of record revenue and operating income in 2008,” said Kevin M. Goodwin, SonoSite President and CEO. “We gained operating leverage and expect to achieve an operating margin in 2008 that is toward the upper end of our guidance of 9 -10% as compared to 2.2% in 2007. We are particularly pleased with this accomplishment in light of the difficult US economic environment and its impact on hospital capital spending which we expect will continue into 2009. Customers deferred, but did not cancel, approximately 10% of our forecasted revenue in the fourth quarter.”

Mr. Goodwin continued, “At this juncture in the year, given the US hospital capital spending environment and an anticipated foreign currency headwind, we are planning for revenue growth of 5 -10% in 2009 at current exchange rates, with relatively flat revenue growth in the first three quarters. However as a result of the company’s forward planning, by carefully managing costs, yet continuing to invest in product development, market introductions and channel expansion, we are targeting to increase operating income by 10 -20% in 2009. We have the financial resources, products, technology and market leadership to navigate through this environment and position us well for future, long-term growth.”

As previously disclosed, the company has taken a $3 million charge for expenses related to the termination of acquisition talks and severance payments which were included in the company’s 2008 operating margin guidance provided on October 23, 2008. The fourth quarter of 2008 will also include a gain of $15.7 million resulting from the repurchase of $80.3 million of senior convertible notes the company issued in July 2007.

Mr. Goodwin is presenting today at the J.P.Morgan Annual Healthcare Conference at 3 :00 pm Pacific Time in San Francisco. An audio replay of Mr. Goodwin’s conference presentation can be accessed via the Investors Section of SonoSite’s website at www.sonosite.com and will be available for 30 days.

Fourth quarter 2008 financial estimates are preliminary. SonoSite plans to report 2008 financial results on February 12, 2009 after the close of the financial markets at 1:00 pm Pacific Time.

Conference Call Information
SonoSite will hold a conference call on February 12th at 1:30 pm PT/4:30 pm ET. The call will be broadcast live and can be accessed via the “Investors” Section of SonoSite’s website at www.sonosite.com. A replay of the audio webcast will be available beginning February 12, 2009, at 4:30 pm (PT) until February 26, 2009, at 10:00 pm (PT) by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 7024347 is required to access the replay.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial position and operating results are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reduced spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including a repurchase of a portion of the debt, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

Mr. Goodwin’s presentation will be webcast live on January 12th beginning at 3:00 pm Pacific Time. An audio replay of the presentation will be available for 30 days following and can be accessed via the Investors Section of SonoSite’s website at www.sonosite.com.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

“I have two great big machines in my office, but for a lot of what I’m doing in my day-to-day practice, such as evaluating abnormal bleeding, checking the ovaries or uterine structures for polyps or fibroids - I can do all that with the S-GYN without having to move my patient out of the exam room,” said Shaunie Keys, MD of Evergreen Women’s Care, in Kirkland, WA. “A big advantage of the S-GYN system is its portability and that I don’t have to disrupt work flow by shuffling patients to different rooms or interrupt my ultrasound tech’s schedule. It’s easy to learn and provides really good imaging. My patients feel more confident knowing that I will complete the ultrasound exam and they will have their results before leaving the office.”

SonoSite has engineered the S-GYN system to enable gynecologists to provide answers to their patients quickly. It integrates SonoSite’s proprietary SonoHD™ and SonoMB™ technologies to provide crystal clear imaging of common gynecologic problems and to guide interventional procedures. With SonoSite’s SonoAdapt™ technology, the clinician need only adjust two controls –Depth and Gain – to quickly acquire the optimum image. The small footprint of the S-GYN fits easily beside the patient examining table and it can be ceiling or wall mounted to save critical space in a cramped setting.

The S-GYN tool is configured to use the C60x abdominal and ICTx transvaginal transducers and comes with SonoSite’s industry-leading 5-year warranty, which covers the system and transducers and eliminates the need for costly annual service contracts. SonoSite also offers extensive training and education programs delivered on site, online and in collaboration with leading medical institutions and educators. The company plans to begin customer shipments before year-end.

The S-GYN system joins the family of other S Series™ systems including: the S-Nerve™ for anesthesiologists, the S-Cath™ for interventionalists, the S-ICU™ for intensivists, the S-FAST™ for emergency medicine physicians and S-MSK™ for musculoskeletal specialists.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

“We are very pleased to contract with one of the nation’s most respected health purchasing groups,” said Kevin M. Goodwin, SonoSite President and CEO. “SonoSite’s products provide medical professionals with the power of ultrasound visualization and the benefits of hand-carried portability in an easy-to-use, rugged design that comes with the industry’s only standard 5-year warranty.”

SonoSite’s portable ultrasound products provide point-of-care imaging across multiple clinical applications. Using SonoSite hand-carried ultrasound, the HealthTrust membership will have access at the point-of-care to ultrasound diagnostic imaging and real-time visual guidance for interventional procedures.

About HealthTrust Purchasing Group
HealthTrust Purchasing Group, headquartered in Brentwood, Tenn., is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than $15 billion, HealthTrust is committed to obtaining the best price for clinically-recommended products, ensuring their timely delivery and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. HealthTrust is located at 155 Franklin Road, Suite 400, Brentwood, TN 37027. The Web site is www.healthtrustpg.com.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

“SonoSite has led the way with innovative products designed for point-of-care use,” said Diku Mandavia, MD, FACEP, FRCPC, Attending Staff, Department of Emergency Medicine, Cedars-Sinai Medical Center and Clinical Associate Professor Emergency Medicine, LA County + USC Medical Center, Los Angeles. “Both the U.S. Agency for Health Care Research and Quality (AHRQ) and the National Institute for Clinical Excellence (NICE) in the UK have recommended ultrasound guidance of central vascular access as a standard of care for ensuring patient safety. It’s difficult to imagine practicing emergency medicine today without ultrasound guidance.”

“Using ultrasound reveals anatomy previously unseen. It removes the practitioners’ blindfold, and allows them to first confirm whether a procedure is indicated and then perform the procedure more safely and effectively by visually guiding the intervention,” said Paul R. Sierzenski, MD, RDMS, FAAEM, FACEP, Director of Emergency, Trauma and Critical Care Ultrasound, and Director, Emergency Ultrasound Fellowship, Christiana Care Health System of Newark, Delaware. “Evidence-based medicine has shown that ultrasound guidance improves accuracy and decreases the number of attempts to correctly place both peripheral and central venous access, which in turn results in efficient and superior patient care. Further, when compared to the landmark technique, using ultrasound allows a visual confirmation of vessel position and patency in addition to the benefits associated with needle guidance. The S-FAST Vascular Access option provides an excellent entry point for emergency departments wanting to incorporate the benefits of ultrasound into their practice.” ¹

Shown at the recent annual meeting of the American College of Emergency Physicians (ACEP) in Chicago, the S-FAST Vascular Access option includes the L25x/13-6 MHz linear array transducer for high resolution vascular imaging and access. The S-FAST device can be used on a stand or be mounted on the wall or from the ceiling to free up space in crowded examination areas.

The form factor of the S-FAST ultrasound tool represents a dramatic departure for ultrasound and offers a highly intuitive user interface that is easy to learn and quick to deploy. Buttons, dials and menus have been stripped to the essentials. Advanced, proprietary algorithms allow emergency medicine physicians to get the optimum image by adjusting only two controls - Depth and Gain. Ready to image in seconds from a cold start, the S-FAST ultrasound tool exceeds military specifications for ruggedness and a sealed user interface resists contamination from bodily fluids and can be wiped down with disinfectant. The S-FAST system is based on an expandable platform so customers can add capabilities, often as software upgrades, as their department requirements change.

As with SonoSite’s other S Series products, the S-FAST Vascular Access option comes with an industry-leading 5-year warranty on the system and transducer. SonoSite also offers extensive training and education programs delivered on site, online and in collaboration with leading medical institutions and educators.

¹Drs. Mandavia and Sierzenski are educational consultants to SonoSite.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

BOTHELL, WA - October 30, 2008 - SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried ultrasound for point-of-care medicine, today announced that it has repurchased in the open market an aggregate of $60.3 million of the principal outstanding amount of its 3.75% convertible notes due 2014 for total consideration of approximately $47.4 million in cash, excluding accrued interest. Following these repurchases, convertible notes representing $164.7 million of principal debt are outstanding.

As a result of the repurchases that have occurred to date, SonoSite expects to report a pre-tax gain of approximately $11 million, net of deferred issuance costs, in the fourth quarter.

In connection with the issuance of these convertible notes in July 2007, SonoSite entered into a convertible note hedge transaction and a warrant transaction with an affiliate of one of the underwriters. These transactions were intended to reduce the potential dilution to SonoSite’s shareholders upon any conversion of the notes. As a result of the recent repurchases, the associated convertible note hedges and a corresponding number of warrant positions will be unwound. The payment received from unwinding the associated convertible note hedges, less the cost of the warrant transaction, will result in net proceeds to SonoSite of approximately $400,000.

SonoSite currently has in excess of $280 million in cash and investments. SonoSite’s board of directors has authorized the repurchase of additional convertible notes in the open market or in privately negotiated transactions as management deems appropriate. In the event of additional repurchases, the company would continue to unwind the associated hedges and a corresponding number of warrant positions.

Conference Call Information
SonoSite will hold a conference call today at 1:30 pm PT/4:30 ET. The call will be broadcast live and can be accessed via the “Investors” section of SonoSite’s website at www.sonosite.com. A replay of the audio web cast will be available beginning October 30, 2008, 4:30 pm PT and will be available until November 13, 2008, midnight PT by dialing (719) 457-0820 or toll-free (888) 203-1112. The confirmation code 4566842 is required to access the replay. The call will also be archived on SonoSite’s website at http://ir.sonosite.com.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

Forward-looking Information and the Private Litigation Reform Act of 1995
Certain statements in this press release relating to our future financial position as a result of any ongoing repurchase of our outstanding senior convertible debt and related financing activities are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance or results and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect our financial position generally and, therefore, impact the timing and magnitude of any possible future repurchase of notes include, among other things, our ability to successfully manufacture, market and sell our ultrasound systems, our ability to accurately forecast customer demand for our products, our customers’ ability to finance the purchase of our systems, including the effect of reducing spending by hospitals, our ability to manufacture and ship our systems in a timely manner to meet customer demand, variability in quarterly results caused by the timing of large project orders from governmental or international entities and the seasonality of hospital purchasing patterns, timely receipts of regulatory approvals to market and sell our products, regulatory and reimbursement changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners and other sales channels to market and sell our products and any changes to such channels, the impact of patent litigation, our ability to execute our acquisition strategy, the effect of transactions and activities associated with our issuance of senior convertible debt in July 2007, including the ongoing repurchase of a portion of the outstanding debt and the continued unwinding of a portion of the related derivative positions in our common stock, on the market price of our common stock, and as well as other factors contained in the Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“SonoGT technology demonstrates the intrinsic capabilities of the M-Turbo system architecture to address our global, multiple point-of-care markets with targeted solutions,” said Kevin M. Goodwin, SonoSite President and CEO. “This advance is aimed at increasing imaging capabilities and clinical productivity and includes a wide range of new technologies and options.”

The company plans to begin customer shipments of new M-Turbo systems with SonoGT technology in the fourth quarter. Customers can separately purchase SonoGT technology and upgrade existing M-Turbo systems via an easy software download from a USB thumb drive. The new SonoGT technology platform offers the following capabilities:

Color Performance

• ColorHD™ Technology - A proprietary, color Doppler algorithm that harnesses the power of the M-Turbo system’s digital signal processor to increase color performance, sensitivity and frame rates. Available on all transducers, ColorHD technology works in parallel with multiple M-Turbo algorithms, including SonoHD™ imaging technology, to provide increased diagnostic information and better visualization of color flow, particularly in low flow states. ColorHD technology also comes with a variable sector size for the P10x/8-4 MHz and the P21x/5-1 MHz phased array transducers for increased frame rates during cardiac imaging.

Wireless Solutions

• SonoRemote™ Control - A new accessory enabled by the SonoGT technology platform untethers the clinician from the ultrasound system during procedures to increase ergonomic comfort and is expected to be very useful in sterile field procedures. Based on Bluetooth® wireless technology, the SonoRemote control can operate within a sterile bag or sheath and can be used to adjust system controls from within a radius of 10 meters. SonoSite plans to begin shipping this option in the first quarter of 2009.
• SonoRoam™ Technology - Using 802.11b/g technology, SonoRoam technology enables wireless image transfer from the M-Turbo system to a PACS system via DICOM® and to a personal computer via SonoSite’s SiteLink™ so that clinicians can quickly retrieve the information from any location. Wireless connectivity is increasingly viewed as a critical component to reduce medical errors and speed time to diagnosis in a portable ultrasound system.

Workflow Integration

• DICOM Storage Commit and DICOM Modality Performed Procedure Step have been added to the M-Turbo system to complete the IHE profile (Integrating the Healthcare Enterprise) Scheduled Workflow (SWF) Integration Profile. This facilitates seamless clinical integration of ordering, scheduling, image acquisition, storage, viewing and billing of patient procedures.
• Patient Management - Patient demographics can now be entered before, during or after the exam. This allows flexibility in getting the procedure completed in time-critical situations where documentation is secondary to that of the procedure itself. DICOM Multi-Modality Worklist (MWL) queries can be made to the hospital information network to gain quick access to patient scheduling for ultrasound and non-ultrasound procedures.
• New USB Bar Code Reader - This accessory allows clinicians to quickly and accurately enter patient information and update exam information prior to its entry into the patient record. SonoSite’s bar code reader now is powered through a USB port freeing AC power for another device.

New Exam Types

• Ophthalmic Exam - The L25x/13-6 MHz transducer offers an ophthalmic exam setting for evaluation of globe rupture, intraocular foreign bodies, and retinal detachment.
• TCD and Orbital Exam - The P21x/5-1 MHz transducer is optimized for assessment of intracranial blood flow and structures.

About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care. The company employs over 600 people worldwide.

Bluetooth and DICOM are registered trademarks or trademarks of their respective owners.

]]> http://www.sonosite.com/sonosite/news/2008/10/27/sonosite-announces-powerful-new-technology-for-m-turbo-system/feed http://www.sonosite.com/sonosite/news/2008/10/27/sonosite-announces-powerful-new-technology-for-m-turbo-system